Literature DB >> 27718290

PKR regulates LPS-induced osteoclast formation and bone destruction in vitro and in vivo.

J Teramachi1, Y Inagaki2, H Shinohara1,2, H Okamura1, D Yang1, K Ochiai3, R Baba4, H Morimoto4, T Nagata2, T Haneji1.   

Abstract

OBJECTIVE: In this study, we aimed to clarify the precise mechanism underlying lipopolysaccharide (LPS)-induced osteoclastogenesis in periodontal disease with a special reference to double-stranded RNA-dependent protein kinase (PKR).
MATERIAL AND METHODS: We dissected the role of PKR in LPS-induced osteoclast differentiation and function using primary mouse bone marrow cells and RAW264.7 pre-osteoclastic cell line. We used a rat experimental periodontitis (PD) model induced by ligature placement with a Porphyromonas gingivalis LPS injection (PD rat) and analyzed the therapeutic effects of C16, a PKR inhibitor, on bone loss in PD rats.
RESULTS: Protein kinase is strongly upregulated and phosphorylated by LPS in the osteoclasts. The inhibition of PKR suppressed LPS-stimulated osteoclast formation and activation. PKR inhibition also suppressed the LPS-mediated activation of NF-κB and MAPK, which are critical pathways for osteoclastogenesis. High expressions of PKR were detected in osteoclasts of PD rats, and the treatment with C16 effectively prevented alveolar bone destruction in PD rats.
CONCLUSIONS: PKR plays a pivotal role in LPS-induced bone loss in PD and, thus, has potential as a therapeutic target for PD.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  double-stranded RNA-dependent protein kinase; lipopolysaccharide; osteoclastogenesis; periodontal disease

Mesh:

Substances:

Year:  2016        PMID: 27718290     DOI: 10.1111/odi.12592

Source DB:  PubMed          Journal:  Oral Dis        ISSN: 1354-523X            Impact factor:   3.511


  7 in total

1.  Xanthine Derivative KMUP-1 Attenuates Experimental Periodontitis by Reducing Osteoclast Differentiation and Inflammation.

Authors:  Cheng-Hsiang Kuo; Ban-Hua Zhang; Shang-En Huang; Jong-Hau Hsu; Yan-Hsiung Wang; Thi Tuyet Ngan Nguyen; Chao-Han Lai; Jwu-Lai Yeh
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

Review 2.  Osteoclastogenesis in periodontal diseases: Possible mediators and mechanisms.

Authors:  Mohammed S AlQranei; Meenakshi A Chellaiah
Journal:  J Oral Biosci       Date:  2020-02-17

3.  Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis via NF-κB-NFATc1 signal pathway.

Authors:  Jing Yang; Ruohui Tang; Jin Yi; Yueqi Chen; Xianghe Li; Tao Yu; Jun Fei
Journal:  FASEB J       Date:  2019-03-11       Impact factor: 5.191

4.  Balanced oral pathogenic bacteria and probiotics promoted wound healing via maintaining mesenchymal stem cell homeostasis.

Authors:  Nannan Han; Lu Jia; Lijia Guo; Yingying Su; Zhenhua Luo; Juan Du; Shenghui Mei; Yi Liu
Journal:  Stem Cell Res Ther       Date:  2020-02-14       Impact factor: 6.832

5.  LPS-Induced Inflammation Prior to Injury Exacerbates the Development of Post-Traumatic Osteoarthritis in Mice.

Authors:  Melanie E Mendez; Aimy Sebastian; Deepa K Murugesh; Nicholas R Hum; Jillian L McCool; Allison W Hsia; Blaine A Christiansen; Gabriela G Loots
Journal:  J Bone Miner Res       Date:  2020-08-03       Impact factor: 6.741

6.  TGF-β-activated kinase-1 inhibitor LL-Z1640-2 reduces joint inflammation and bone destruction in mouse models of rheumatoid arthritis by inhibiting NLRP3 inflammasome, TACE, TNF-α and RANKL expression.

Authors:  Hirofumi Tenshin; Jumpei Teramachi; Mohannad Ashtar; Masahiro Hiasa; Yusuke Inoue; Asuka Oda; Kotaro Tanimoto; So Shimizu; Yoshiki Higa; Takeshi Harada; Masahiro Oura; Kimiko Sogabe; Tomoyo Hara; Ryohei Sumitani; Tomoko Maruhashi; Mayu Sebe; Rie Tsutsumi; Hiroshi Sakaue; Itsuro Endo; Toshio Matsumoto; Eiji Tanaka; Masahiro Abe
Journal:  Clin Transl Immunology       Date:  2022-01-19

Review 7.  Protein Kinase R in Bacterial Infections: Friend or Foe?

Authors:  Robin Smyth; Jim Sun
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.